Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This was an open-label, randomized controlled trial that aims to compare the efficacy and
safety of the concurrent neoadjuvant chemotherapy with endocrine therapy and neoadjuvant
chemotherapy alone in ER-positive, HER2-negative breast cancer.